The article presents the result of study of the effectiveness of a new drug dexlansoprazole in combination with the drug ursodeoxycholic acid in the group of patients with erosive esophagitis, with mixed reflux, as defined by results of 24-hour pHimpedance metering. Dynamics of clinical symptoms and endoscopic pattern when taking different doses of UDCA of primary and supportive therapy is monitored.
